Study details
Enrolling now
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
AbbVie
NCT IDNCT06880744ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
530
Study length
about 3.3 years
Ages
18–80
Locations
74 sites in AL, AZ, CA +24
About this study
Researchers are testing whether risankizumab or vedolizumab are effective treatments for adults with moderate to severe ulcerative colitis who haven't received targeted therapies before. The trial will last about 69 weeks, and participants will receive either risankizumab (IV then subcutaneous) or vedolizumab (IV throughout).
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Risankizumab
- 2.Take Vedolizumab
PhasePhase 3
DrugRisankizumab
Routeinjection
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low5%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
risankizumab, vedolizumab
Drug routes
injection, intravenous
Body systems
Gastroenterology